Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Acceleron Pharma Inc. (XLRN)

« Back to company index

XLRN Chatter Timeline

Stock Ticker for XLRN

Most Active Tweeters for XLRN

UserTweets
@TickerReport 4
@AmericanBanking 2
@WatchlistN 2
@dailypoliticaln 2
@dailymailtimes 2

Recent Tweets for XLRN

bbnsnews @bbnsnews
$27.14 Million in Sales Expected for Acceleron Pharma Inc $XLRN This Quarter https://t.co/H7UQfRy5rs
July 13th 2019, 6:07pm
InsiderAlertsIA @InsiderAlertsIA
$XLRN: New Insider Filing on EVP, Chief Business Officer JOHN D QUISEL: https://t.co/uSCAR0CVWt
July 11th 2019, 4:07pm
confcalltran @confcalltran
EVP of ACCELERON PHARMA INC just picked up 8,908 shares https://t.co/ObAEMl4umq $XLRN
July 11th 2019, 4:07pm
Clover_Research @Clover_Research
$XLRN someone will eventually figure out it’ll be more cost effective to buy Acceleron out. https://t.co/kdKjcBfnol
July 11th 2019, 2:07pm
TickerReport @TickerReport
Acceleron Pharma Inc $XLRN Expected to Announce Quarterly Sales of $27.14 Million https://t.co/EJFYuVJWcy
July 11th 2019, 9:07am
TickerReport @TickerReport
Analysts Expect Acceleron Pharma Inc $XLRN to Post -$0.24 EPS https://t.co/EvjLIrBu6J
July 9th 2019, 8:07am
SwingTradeBot @SwingTradeBot
Recent $XLRN technical alerts: Stochastic Sell Signal plus 2 more alerts... https://t.co/9CITuDOmfh
July 8th 2019, 12:07pm
1MinuteStock @1MinuteStock
We calculated 21-day Expected Return of $XLRN for you: 4.29% https://t.co/mSN1RwNHIq
July 8th 2019, 12:07pm
1MinuteStock @1MinuteStock
Btw, Estimated #Earnings Per Share for $XLRN is $-0.64 it's -1.53% of the current price https://t.co/wB8VJQrjbz
July 8th 2019, 12:07pm
midetimes @midetimes
Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Brokerages https://t.co/SrbdadTdlm #stocks
July 7th 2019, 7:07pm
dailypoliticaln @dailypoliticaln
Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Brokerages https://t.co/tYUxm8M5H0
July 7th 2019, 7:07pm
dailymailtimes @dailymailtimes
Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Brokerages https://t.co/y1SRRd2Rta #investing
July 7th 2019, 7:07pm
ZolmaxNews @ZolmaxNews
Analysts Set Acceleron Pharma Inc $XLRN Price Target at $61.22 https://t.co/ngaU3SMVpP
July 7th 2019, 7:07pm
AmericanBanking @AmericanBanking
Acceleron Pharma Inc $XLRN Expected to Announce Quarterly Sales of $27.14 Million https://t.co/abPI44mSG8 #stocks
July 6th 2019, 1:07am
WatchlistN @WatchlistN
Acceleron Pharma Inc $XLRN Given Consensus Recommendation of “Buy” by Analysts https://t.co/KGqByCp2gg
July 5th 2019, 6:07pm
SwingTradeBot @SwingTradeBot
Recent $XLRN technical alerts: Upper Bollinger Band Walk plus 7 more alerts... https://t.co/9CITuDOmfh
July 5th 2019, 3:07pm
FlashAlert_me @FlashAlert_me
$XLRN filed form CT ORDER on July 05, 09:51:41 https://t.co/ZH2KYZTsWy
July 5th 2019, 9:07am
Biotech2050 @Biotech2050
RT @semodough: $XLRN $CELG company continues to work towards potential luspatercept approval. XLRN/Celgene filed the luspatercept BLA/MAA i…
July 5th 2019, 7:07am
semodough @semodough
$XLRN $CELG company continues to work towards potential luspatercept approval. XLRN/Celgene filed the luspatercept… https://t.co/qUK755RI09
July 5th 2019, 7:07am
AmericanBanking @AmericanBanking
Zacks: Analysts Anticipate Acceleron Pharma Inc $XLRN to Post -$0.24 Earnings Per Share https://t.co/ogdGNmP9jz #stocks
July 5th 2019, 12:07am
WKRBNews @WKRBNews
-$0.24 Earnings Per Share Expected for Acceleron Pharma Inc $XLRN This Quarter https://t.co/fxVCauildt #markets
July 5th 2019, 12:07am
ZolmaxNews @ZolmaxNews
Zacks: Analysts Anticipate Acceleron Pharma Inc $XLRN to Post -$0.24 Earnings Per Share https://t.co/VDikFxoucZ
July 5th 2019, 12:07am
midetimes @midetimes
Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/vH5w1b4trP #stocks
July 4th 2019, 1:07am
dailymailtimes @dailymailtimes
Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/8VAzw3Iy0M #investing
July 4th 2019, 1:07am
dailypoliticaln @dailypoliticaln
Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/fnhwOgZKdK
July 4th 2019, 1:07am
WatchlistN @WatchlistN
Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/iKvQogxSaq
July 4th 2019, 1:07am
WeekHerald @WeekHerald
Acceleron Pharma’s $XLRN “Hold” Rating Reiterated at Zacks Investment Research https://t.co/Ugycs0hFZG
July 3rd 2019, 2:07am
ThisLincolnian @ThisLincolnian
Zacks Investment Research Reiterates “Hold” Rating for Acceleron Pharma $XLRN https://t.co/n8tX3hY5fD
July 3rd 2019, 2:07am
ConsumerFeed @ConsumerFeed
Acceleron Pharma $XLRN Stock Rating Reaffirmed by Zacks Investment Research https://t.co/JBXrupx1iK
July 2nd 2019, 1:07am
ConsumerFeed @ConsumerFeed
Acceleron Pharma $XLRN Stock Rating Reaffirmed by Zacks Investment Research https://t.co/R29W7i0ExM
July 2nd 2019, 1:07am
TickerReport @TickerReport
Acceleron Pharma’s $XLRN Hold Rating Reaffirmed at Zacks Investment Research https://t.co/FbjGblq1Gu
July 2nd 2019, 1:07am
TickerReport @TickerReport
Acceleron Pharma’s $XLRN Hold Rating Reaffirmed at Zacks Investment Research https://t.co/4fS2PaHnfN
July 2nd 2019, 1:07am
Gambiste1 @Gambiste1
RT @IlliniJJ: $XLRN - two 2H 2019 and two 1Q 2020 data readouts. In addition Luspatercept has 2 upcoming PDUFA dates. https://t.co/5sCO8mm…
July 1st 2019, 6:07pm
IlliniJJ @IlliniJJ
$XLRN - two 2H 2019 and two 1Q 2020 data readouts. In addition Luspatercept has 2 upcoming PDUFA dates. https://t.co/5sCO8mmMDz
July 1st 2019, 11:07am
AmericanBanking @AmericanBanking
Acceleron Pharma Inc $XLRN Receives Average Recommendation of “Buy” from Analysts https://t.co/dz72SufLUo #stocks
June 30th 2019, 7:06am
ZolmaxNews @ZolmaxNews
Jean George Sells 25,688 Shares of Acceleron Pharma Inc $XLRN Stock https://t.co/3TdGjtqSU6
June 30th 2019, 4:06am
TickerReport @TickerReport
Jean George Sells 37,500 Shares of Acceleron Pharma Inc $XLRN Stock https://t.co/vzR1RET5py
June 30th 2019, 4:06am
1MinuteStock @1MinuteStock
Recommendation #HOLD for $XLRN with UB rating - 2.62 out of 5. https://t.co/V323QXjJDi
June 28th 2019, 10:06pm
InsiderAlertsIA @InsiderAlertsIA
$XLRN: New Insider Filing on Director JEAN GEORGE: https://t.co/nT97yOiE3J
June 28th 2019, 9:06pm
insiderbuyings @insiderbuyings
$XLRN new insider selling: 37500 shares. https://t.co/Ca3gOE5sTn
June 28th 2019, 9:06pm
AmericanBanking @AmericanBanking
Insider Selling: Acceleron Pharma Inc $XLRN Director Sells 37,500 Shares of Stock https://t.co/TmYMOVoc52 #stocks
June 28th 2019, 8:06pm
HCWCO @HCWCO
Yesterday, $XLRN announced target enrollment achieved in PULSAR Phase 2 trial. More in today’s Morning Summary:… https://t.co/rHZx6bkrrS
June 27th 2019, 3:06pm
tradnews_ @tradnews_
RT @AlertTrade: TREND REVERSAL UP ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room
June 27th 2019, 12:06pm
AlertTrade @AlertTrade
TREND REVERSAL UP ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room
June 27th 2019, 12:06pm
newswelldone @newswelldone
$XLRN: Acceleron completes enrollment in mid-stage study of sotatercept in …: https://t.co/le1ZGQIXPh
June 26th 2019, 8:06am
ToothFrank @ToothFrank
$XLRN Completes Enrollment in the PULSAR Phase 2 Trial of Sotatercept in PAH. Topline Data Q1'20
June 26th 2019, 8:06am
MarketCurrents @MarketCurrents
$XLRN - Acceleron completes enrollment in mid-stage study of sotatercept in PAH https://t.co/8Z2ojtcDoE
June 26th 2019, 7:06am
ProVesting @ProVesting
$XLRN: Acceleron Completes Target Enrollment in the PULSAR Phase 2 …: https://t.co/qPiIdf6y9S
June 26th 2019, 7:06am
TranscriptDaily @TranscriptDaily
Acceleron Pharma $XLRN Upgraded to “Hold” at Zacks Investment Research https://t.co/IdSk4U7O9o
June 26th 2019, 3:06am
registrarjourn @registrarjourn
Acceleron Pharma $XLRN Upgraded to “Hold” at Zacks Investment Research https://t.co/aRMH0xl8wt
June 26th 2019, 3:06am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.